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Purpose. To estimate the US prevalence of Peyronie’s disease (PD) from patient-reported data and to identify diagnosis and
treatment patterns. Methods. 11,420 US males ≥18 years old completed a brief web-based survey regarding the presence of PD,
past treatments, and penile symptoms (Phase 1). Phase 1 respondents with PD diagnosis, history of treatment, or PD-related
symptoms then completed a disease-speciﬁc survey (Phase 2). Results. Estimated prevalence of PD ranged from 0.5% (diagnosis of
PD) to 13% (diagnosis, treatment, or penile symptoms). Thirty-six percent of Phase 2 participants reported that penile symptoms
interfered with sexual activities. Of participants who sought treatment for penile symptoms (n = 128), 73% initially saw a primary
care physician, 74% did not receive treatment from their ﬁrst doctor, and 92% were not diagnosed with PD. Conclusions.P Dm a y
be underdiagnosed/undertreated in the US. Improved awareness is needed of PD symptoms and treatment options among health
care professionals.
1.Introduction
Peyronie’s disease (PD) is a progressive ﬁbrotic tissue disor-
der with unknown etiology [1–3]. It is a connective tissue
disorder of the penile tunica albuginea that results in the
formation of a palpable scar or hard plaque, most commonly
on the dorsal surface of the penis, which may cause a cur-
vature deformity and changes in the length or circumference
of the penis while erect. Penile folding or collapsing during
intercourse, penile pain, and erectile dysfunction (ED) are
also associated with PD [1]. In a recent retrospective study of
1,001 patients with PD, 58.1% of patients reported having
ED [4]. PD may also limit the ability to have intercourse
andmaymakeintercourselessenjoyable,moreawkward,and
even impossible. PD can be psychologically and physically
devastating for patients and can also negatively impact part-
ner relationships [5, 6].
The disease is not well understood, and consequently,
patients are often misdiagnosed (e.g., with ED) and the time
to diagnosis and treatment can be long. Current theories
regardingthecauseofPDsuggestthatavarietyoffactorsmay
be involved, such as a traumatic event, sometimes related
to sexual intercourse, the presence of genetic predisposi-
tion, or occurrence of abnormal wound healing, including
involvement of transforming growth factor β-1 or other pro-
ﬁbrotic factors [7, 8]. Convincing evidence regarding the
pathophysiology, diagnosis, and treatment of PD continues
to elude physicians [9].
To date, there are no Food and Drug Administration-
(FDA)-approved, nonsurgical options for treatment of PD,
and clinically proven treatment options are limited. Current
nonsurgical treatment options for PD include oral, trans-
dermal, or intralesional injection, extracorporeal shock wave
therapy, or external traction therapy [1, 10–13]. The eﬃcacy
of many nonsurgical treatments is unknown due to under-
powered and methodologically heterogeneous treatment
studies[10].SurgicalinterventionsforPDmayfollowunsuc-
cessful nonsurgical treatment options and are primarily con-
sidered for patients with deformity that impairs sexual
function [14]. It is recommended that surgery be delayed2 Advances in Urology
Table 1: Prevalence of Peyronie’s disease from the literature.
Patient population Prevalence
(%)
Arafa et al. 2007 [17] Diabetic patients with
erectile dysfunction 20.3
Mulhall et al. 2004 [21] Men screened for
prostate cancer 8.9
El-Sakka 2006 [18] Patients with erectile
dysfunction 7.9
La Pera et al. 2001 [19] General population 7.1
Rhoden et al. 2001 [22]
Men older than 50 years
undergoing prostate
cancer screening
3.67
Schwarzer et al. 2001
[23], Sommer et al. 2002
[24]
General population 3.2
Lindsay et al. 1991 [20] General population 0.39
until the disease has stabilized for at least 6 to 12 months
and the active inﬂammatory disease process involving penile
pain and recent changes in penile deformity has concluded
[1]. Surgical correction has its limitations, including penile
shortening in many procedures, recurrence of curvature, al-
tered penile sensation, development of new-onset ED, and
the potential rare complications of surgery, such as bleeding
or infection [14–16].
The prevalence of PD is not known. Studies of PD prev-
alence are limited and inconsistent; estimates have ranged
from 0.39% to greater than 20% (see Table 1)[ 17–24]. Prev-
alence can range based on study design or inclusion of
patients with diﬀerent comorbidities within the study pop-
ulation (e.g., older age, diabetes, and ED). In addition,
the actual occurrence of this disease within the population
may be higher due to patients’ reluctance to come to their
physician for treatment and diagnosis of this embarrassing
condition [25]. Limited understanding of PD in the medical
community may also contribute to underdiagnosis.
The current study was motivated by the lack of the cur-
rent PD epidemiological data from the general US popula-
tion and the need to understand how patients and physicians
perceive this disease in regards to diagnosis and treatment.
The current study is web-based survey of US male adults
aged 18 years or older who were enrolled in a probability-
based panel of research subjects representative of the full
US population (Knowledge Networks; KN) [26]. The study
objectives were (1) to estimate the prevalence of PD in
the general US male population, (2) to determine the time
from ﬁrst symptom noticed to medical treatment, and (3) to
describe diagnosis and treatment patterns. Analyses of these
objectives were based on patient-reported data.
2. Methods
2.1. Study Design. This cross-sectional, population-based
survey was conducted in 2 phases (Figure 1). In the initial
phase (Phase 1), participants from the KN online panel were
screened for the presence of current symptoms of PD, past
KN database
16,000 invited panel participants (men ≥18 years old)
• Diagnosis of PD
• Diagnosis or treatment of PD
• Diagnosis, treatment, or penile symptoms
Subsample
Diagnosis and/or
treatment of
Peyronie’s
reported in
Phase 2
Phase 2 Phase 2
Subsample
Random selection
of those reporting
Peyronie’s
symptoms in
(n = 84) (n = 199)
Eligibility criteria for Phase 2
283 participants completed Phase 2 survey
Phase 11,420 participants completed 1 survey
Phase 1 Phase 1
Figure 1: Diagram of study design. Data for this study were
collected in 2 phases. In Phase 1, panel participants were screened
for the presence of symptoms, past treatment, and a diagnosis of
Peyronie’s disease. In Phase 2, eligibility to complete the full survey
was determined by participants’ responses to the screening items in
Phase 1. KN = Knowledge Networks.
surgical or nonsurgical treatments, and a diagnosis of PD.
Data from Phase 1 was used to estimate the prevalence of PD
in the general US population and to determine eligibility to
completethefullsurveyinPhase 2.InthePhase 2portionof
the study, a subsample of Phase 1 participants meeting the
eligibility criteria for PD were invited to complete the PD
survey (see the Appendix), which focused on the presence
and severity of current symptoms, family history, and treat-
ment history for penile symptoms.
The KN panel, a proprietary web-enabled panel of indi-
viduals who have agreed to participate in ongoing survey
research is the only known online panel based on a random-
digit-dialing sample of the full US population, ensuring that
the panel is representative of the US population [26]. KN
provides panelists “points” that can be redeemed for cash
at regular intervals for panel participation (for those withAdvances in Urology 3
Internet access) or with web-enabled technology to ensure
that those who would not otherwise have access to the
Internet are able to participate in KN surveys [26]. The KN
panel has been used to estimate prevalence previously in
several diﬀerent studies [27–29].
The current study was structured in a way that allowed
for patient conﬁdentiality in both phases: identifying patient
information was never transmitted or provided to study per-
sonnel and KN did not link patient contact information
and survey responses. Following ethics committee approval
by RTI International’s Institutional Review Board, screening
in Phase 1 was ﬁelded from November 6, 2007, through
December 9, 2007, and the Phase 2 survey was ﬁelded
from March 20, 2008, through March 31, 2008. Prior to
administration of either Phase 1 or Phase 2 surveys, all
participants provided written informed consent.
2.2. Participants. A total of 16,000 men aged 18 years and
older residing in the US were randomly selected from the KN
online panel and invited to participate in the current study.
Individuals eligible for Phase 1 included all adult men (aged
18yearsorolder)whowereKNpanelmembersatthetimeof
Phase 1 recruitment. Eligibility for the PD full survey (Phase
2)wasbasedonresponsestothescreeningquestionsinPhase
1. Speciﬁcally, Phase 1 respondents eligible for Phase 2 were
those who reported 1 or more of the following criteria at
screening:
(1) ever received a diagnosis of PD by a doctor or other
health care professional,
(2) ever received either surgery or a nonsurgical proce-
dure to correct the shape of the penis,
(3) currently have at least 1 of the following symptoms:
(i) a lump or bump (excluding genital warts, pim-
ples, and blisters) under the skin of the penis
when the penis is not erect,
(ii) an area of unusual ﬁrmness or hardened tissue
(excluding genital warts, pimples, and blisters)
undertheskinofthepeniswhenthepenisisnot
erect,
(iii) a change in erect penis that includes at least 1 of
the following symptoms:
(a) a signiﬁcant bend or curve of the penis,
(b) an indentation on 1 or both sides of the penis,
(c) a noticeable narrowing of the penis, like an
hourglass or band around the penis, or a fold-
ing, like a hinge, of the penis during sexual
intercourse.
Inaddition,respondentswithchordee(congenitalcurva-
ture of the penis) were eligible only if they reported (1) one
of the above-mentioned symptoms other than a signiﬁcant
bend or curve of the penis or (2) a diagnosis of PD. A total
of 27 patients had chordee and 12 of them were eligible for
Phase 2, and all of them met additional criteria for inclusion
in the study. Speciﬁcally, 2 of them reported diagnosis of PD,
1 had received treatment for PD, and 9 had other qualifying
symptoms of PD.
2.3. Sampling Method for the Phase 2 Peyronie’s Disease Sur-
vey. Participants invited to complete Phase 2 were selected
using a stratiﬁed random sampling approach based on the
following 2 strata: (1) participants reporting treatment
and/or diagnosis (Stratum 1) and (2) participants reporting
symptoms only (Stratum 2). To ensure an adequate sample
size to evaluate treatment patterns, respondents reporting
prior treatment or a diagnosis for PD in Phase 1 were over-
sampled in Phase 2.
After excluding respondents who were no longer active
in the KN panel, all respondents from Stratum 1 (diagnosis
and/or treatment) were invited to complete the Phase 2 PD
survey. In addition, to ensure that at least 200 completed
patient surveys could be obtained, 314 participants from
Stratum 2 (symptoms only) were randomly selected to com-
plete the Phase 2 PD survey.
2.4. Questionnaire Content. The Peyronie’s portion of the
screener administered in Phase 1 contained questions assess-
ing the presence of various penile-related symptoms, diag-
nosis of PD, and past surgical or nonsurgical treatments for
penile-related symptoms (see the Appendix).
The Peyronie’s survey in Phase 2 focused on the presence
and severity of current symptoms, family history, and treat-
ment history for penile symptoms (e.g., speciﬁc symptom
ﬁrst noticed, time from noticing ﬁrst symptom until seeking
medical treatment, other symptoms noticed, types of treat-
ment received and success of each treatment type, length
of treatment/duration of care, number of surgeries and/or
nonsurgical procedures, diagnoses received, and types of
physicians treating and/or diagnosing the disease).
2.5. Data Analysis
2.5.1. Prevalence Estimates. The prevalence estimates of PD
were based on self-reported data from Phase 1 and adjusted
to represent the US population by using statistical weights
provided by KN. These weights are designed to (1) account
fortheknownsourcesofdeviationfromanequal-probability
selection design during formation of the KN panel, (2)
reducebiasduetononcoverageofnontelephonehouseholds,
and (3) reduce the nonresponse bias potentially introduced
during data collection for outcomes highly correlated with
demographic and geographic characteristics.
Three diﬀerent prevalence estimates for PD were calcu-
lated. The numerators for the prevalence estimates of PD
were derived using the following 3 criteria, ordered from
mosttoleaststringent,andthedenominatorwasthenumber
of individuals who completed Phase 1.
Criterion 1. Participant has received a diagnosis of PD from
a doctor or other health care professional.
Criterion 2. Participant meets Criterion 1 or has ever had
surgery and/or a nonsurgical procedure to correct the shape
of the penis.4 Advances in Urology
Table 2: Demographic characteristics of Phases 1 and 2 male participants.
Phase 2 participants (n = 283)
Characteristic Category Phase 1 participants
(n = 11,420)
With diagnosis/treatment
(n = 84)
With symptoms and
no diagnosis/treatment
(n = 199)
n (%) n (%) n (%)
Age (years)
Mean (SD) 52.7 (15.0) 59.6 (11.9) 49.6 (17.0)
Median 53 60 50
Range 18–101 20–87 18–89
Race
White, non-Hispanic 9803 (86%) 76 (90%) 137 (69%)
Black, non-Hispanic 571 (5%) 3 (4%) 25 (13%)
Other, non-Hispanic 544 (5%) 5 (6%) 14 (7%)
Hispanic 502 (4%) 0 (0%) 23 (12%)
Education
Less than high school 588 (5%) 3 (4%) 16 (8%)
High school 2098 (18%) 8 (10%) 57 (29%)
Some college 3898 (34%) 32 (38%) 58 (29%)
Bachelor’s degree or higher 4836 (42%) 41 (49%) 68 (34%)
SD: standard deviation.
Criterion 3. Participant meets Criterion 2 or has penile
plaque or a deformity as indicated by an aﬃrmative response
to at least 1 of the following: a lump or bump under the
skin of the penis when penis is not erect, unusual ﬁrmness
or hardened tissue under the skin of the penis when penis is
not erect, bend or curve when the penis is erect, indentation
when the penis is erect, noticeable narrowing, like an
hourglass, when the penis is erect, or folding like a hinge
when the penis is erect
A participant with chordee did not meet PD criteria un-
less he also reported at least 1 of the following symptoms:
lump, ﬁrmness, indentation, narrowing or folding, or a di-
agnosis of PD by a physician or other health care provider.
2.5.2. Analysis of Phase 2 Peyronie’s Disease Survey. As de-
scribed previously, the PD survey was administered in
Phase 2 to a stratiﬁed random sample of patients indicating
a diagnosis of PD, and/or treatment for penile symptoms
(Stratum 1), or presence of penile symptoms (Stratum 2).
Because patients reporting a diagnosis or treatment were
oversampled, summary statistics (i.e., means or percentages)
were calculated using weighted averages of the stratum-
speciﬁc estimates to obtain an overall estimate among the
eligible participants across the 2 strata (treatment/diagnosis
and symptom only) [30]. No imputations were made for
missing values. When calculating percentages, participants
whodidnotansweraparticularquestionwereexcludedfrom
the denominator for that question.
3. Results
Of the 16,000 men aged 18 years and older who were
randomly selected from the pool of KN panel members
and invited to participate in Phase 1, a total of 11,420
completed the screening survey for a response rate of 71%.
In Phase 1 of the study, 415 PD patients were identiﬁed (101
of them reported a PD diagnosis and/or surgical/nonsurgical
treatment) and invited to complete a full survey in Phase 2.
Of those invited to participate, 283 (68%) consented and
completed the PD full survey in Phase 2.
3.1. Demographic Characteristics. Table 2 presents unweight-
eddemographiccharacteristicsforallrespondentsinPhase 1
as well as respondents to the PD survey in Phase 2. The
mean age of all respondents in Phase 1 was 52.7 (SD = 15.0)
years. In Phase 2, the mean age of the respondents who had
received a diagnosis or treatment was 59.6 (SD = 11.9) years,
while the mean age for respondents who had symptoms but
were not diagnosed/treated was 49.6 (SD = 17.0) years. The
majorityofrespondentsacrossbothphaseswerewhite(86%)
and had completed at least a high school level of education.
Respondents with symptoms but no diagnosis/treatment
tended to be younger, Black and Hispanic, and less likely
to have post-high-school education compared to those with
diagnosis or treatment.
3.1.1. Prevalence Estimate. The estimated prevalence of PD
based on the 3 criteria ranged from 0.5% to 13%, ordered
from most to least stringent criteria (Table 3).
3.2. Peyronie’s Disease Symptoms and Treatment Patterns.
ResultsfromthePhase 2surveyindicatethat21%ofpatients
with PD diagnosis, treatment, or symptoms reported having
a lump or bump under the skin of their penis, and 21%
reported unusual ﬁrmness or hardened tissue under the
skin of their penis (Table 4). Thirty-seven percent indicated
that these symptoms aﬀected the shape of their penis.
Most patients (95%) reported no painful erections or pain
during intercourse. However, 36% reported penile-related
symptoms that interfered with sexual activities. The most
common ﬁrst penile symptom noticed was a signiﬁcant
bend or curve (32%). Other ﬁrst penile-related symptomsAdvances in Urology 5
Table 3: Estimated prevalence of Peyronie’s disease in US males in
2007.
Phase 1 respondents (n = 11,420)
Disease criteria Prevalence (%) 95% CI
Criterion 1:
Diagnosis of PD 0.5 0.4–0.7
Criterion 2:
Diagnosis or
treatment of PD
0.8 0.5–1.0
Criterion 3:
Diagnosis,
treatment, or any
symptom of PD
13.1 12.0–14.1
CI: conﬁdence interval.
Note: Prevalence estimates are weighted estimates from 11,420 male
respondents.
commonly reported include erections not hard enough for
sexual intercourse (20%), head of penis less hard (12%),
lump or bump under the skin (11%), or shortening of penis
(10%).
Of the 283 PD patients, 128 reported seeing a doctor
for the treatment of penile-related symptoms at some time
during their lifetime. Among these patients, 68% reported
seeing a doctor when they ﬁrst noticed symptoms; the mean
time to see the doctor was 16.8 (SD = 5.5) months. One-
third (32%) of patients spoke with a doctor at a later time;
the mean time to see the doctor was 46.2 (SD = 8.4) months.
The majority (73%) of PD patients seeking treatment ﬁrst
saw a primary care physician (PCP), and 22% ﬁrst saw
a urologist/urology surgeon (note: from here forward, the
term urologist will include urology surgeon). The most
common symptoms that prompted seeking treatment were
erections not hard enough for intercourse (51%), lump or
bump under the skin of the penis (13%), and signiﬁcant
bend or curve in the penis (10%).
Only 8% of treatment-seeking patients reported receiv-
ing a diagnosis of PD from the ﬁrst doctor seen for penile
symptoms;48%reportedreceivingadiagnosisofED.Among
the few that were diagnosed with PD, 59% received the
diagnosis from a urologist, and 41% received the diagnosis
from their PCP.
Treatment was often not given (49%), and patients were
often advised to “wait and see” (25%) from the ﬁrst doctor
seen for penile symptoms. When treatment was eventually
recommended at any doctor visit, the most commonly re-
portedtreatmentswereEDtreatment(17%ofthosewhosaw
a doctor), topical gel applied to the skin of the penis (7%),
vitamin B or potaba (7%), vacuum or stretching therapy
(5%),andvitaminE(5%).Themeantimetotreatmentfrom
theﬁrstnoticedsymptomwas8.9(SD =6.7)months(topical
gel) to 37.0 (SD = 12.3) months (ED therapy).
3.2.1. Summary of Surgical Procedures. Sixteen PD patients
reported undergoing surgery for PD; of these, 14 patients re-
ported 1 surgery and 2 patients reported 3 or more surgeries.
A urologist performed the initial surgery in 81% (13/16)
of participants. The mean time from ﬁrst noticing a penile
symptom until the ﬁrst surgery was 31.8 months (SD
= 64.2 months). The mean time from ﬁrst diagnosis to
ﬁrst surgery was 6.3 months (SD = 6.8 months). Among
respondents, 5 patients reported receiving a prosthetic penile
implant, and 2 patients reported surgical grafting (6 patients
reported “other” surgical procedure). Of the 16 patients who
had surgery performed, 13 reported that the ﬁrst surgery
corrected the penile-related symptoms, and 11 reported that
symptoms did not return, and no new symptoms were re-
ported following surgery.
3.2.2. Summary of Nonsurgical Injection Procedures. Twelve
PD patients reported injections to treat penile symptoms;
10 patients reported 1 series of injections, and 2 patients
reported 5 or more injection series. The ﬁrst injection series
was performed by a urologist in 42% (5/12) of participants,
a PCP in 25% (3/12) of patients, and a sexual medicine
specialist in 25% (3/12) of patients. Among 10 respondents
who provided information around timing of injections, the
ﬁrst injection procedure was an average of 9.7 months
(SD = 14.4 months) from the time the ﬁrst symptom was
noticed. Three of these 10 respondents were diagnosed,
and the average time to the ﬁrst injection series from the
time of ﬁrst diagnosis was 2.3 months (SD = 2.5 months).
Four respondents knew the type of medication received in
the ﬁrst injection series; 2 reported verapamil, 1 reported
testosterone,and1reportedanunspeciﬁed“other”injection.
Six out of 12 patients who had injections to treat penile
symptoms reported that the injections corrected the penile-
related symptoms, and 4 patients reported that symptoms
did not return, and no new symptoms were reported
following the procedure.
4. Discussion
Although PD has been recognized for over 200 years, no
consensus exists with regard to the etiology, prevalence,
treatment, or even the deﬁnition of this condition. The
current study, the ﬁrst large-scale, web-based population
survey of PD among men in the US, showed the estimated
prevalence of PD in the US to range from 0.5% (diagnosis
of PD) to 13% (diagnosis, treatment, or penile symptoms)
using criteria described previously. The estimate of 0.5%
was based on respondent-reported diagnosis by a physician.
The study did not collect information on what exams were
used by the physician to arrive at the diagnosis. However,
this number may be underestimated because most of the
responders of the study did not see a physician even though
they experienced penile symptoms. When including those
reportingpenilesymptoms,theprevalenceincreasedto13%.
The higher prevalence of symptoms of PD compared with
theactualdiagnosissuggeststhatPDmaybeunderdiagnosed
in the US. Additionally, diagnosis of ED and high usage of
ED-related treatments may actually indicate misdiagnosis of
PD symptoms. Underreporting of PD may occur because
aﬀected individuals are not comfortable discussing symp-
toms with health care professionals or are unaware of eﬀec-
tive treatment options. In addition, health care professionals6 Advances in Urology
Table 4: Summary of Peyronie’s disease symptoms in participants with symptoms, treatment, or diagnosis (n = 283).
Statistic or category Participants (n = 283)
(n,% ∗)
Lump or bump under skin of penis Yes 60 (21)
No 222 (79)
Missing 1
Unusual ﬁrmness or hardened tissue under skin of penis Yes 69 (21)
No 210 (79)
Missing 4
Lump/bump, ﬁrmness, or hardened tissue aﬀect the shape of
penis (if yes to either 1 of the above 2 symptoms, n = 87)
Yes 48 (37)
No 39 (63)
Signiﬁcant bend or curve compared to a younger age (erect
penis)
Yes 177 (59)
No 106 (41)
First penis-related symptom noticed Lump or bump under the skin 24 (11)
Area of unusual ﬁrmness or
hardened tissue under the skin 13 (4)
Signiﬁcant bend or curve not
previously noticed 95 (32)
Indentation on 1 or both sides 7 (2)
Noticeable narrowing of the
penis (hourglass or bandlike) 4( 2 )
Hinge-like folding of penis
during sexual intercourse 7( 3 )
Shortening of penis 20 (10)
Head of penis less hard 26 (12)
Painful erections 4 (<1)
Pain during sexual intercourse 5 (2)
Erections not hard enough for
sexual intercourse 51 (20)
Other 8 (3)
Missing 19
∗Percentages are weighted averages of the stratum-speciﬁc estimates.
may not recognize symptoms when presented by patients,
or they may not perform physical exams themselves and
may instead refer patients to a specialist. Not all health care
professionalsmaybeproperlytrainedinthisareaofresearch,
and thus, they may be unaware of available treatments.
It has recently been shown that PCPs and urologists may
not be aware of recent ﬁndings related to the prevalence of
PD, its association with ED, and its responsiveness to avail-
able treatments [31]. Results of a survey by LaRochelle and
Levine found that, contrary to new information regarding
PD, many physicians (63% of PCPs and 41% of urologists)
continue to believe the prevalence of PD is below 1%, and
17% of PCPs and 38% of urologists believed that the disease
remitsspontaneouslyinmorethan50%ofcases[31],despite
the lack of data from available research supporting these
beliefs.
Among PDpatients whoreported a diagnosis, treatment,
or penile symptoms related to PD, interference in sexual
activities was reported by approximately one-third. Thirty-
one percent of patients reported either a lump/bump or
an unusual ﬁrmness or hardened tissue under the skin of
the penis. While this number of patients who identiﬁed a
palpable plaque may seem low, a study of more than 1,500
patients with PD found similar number of patients reporting
plaques (39%), so these results may be more common
than originally suspected [32]. Penile pain is an important
consideration in patients with PD, particularly in the early,
acute phase of PD [33, 34]; however, pain was not declared
by many patients in this study. We cannot make deﬁnitive
conclusions about the absence of reported pain because this
study asked about current symptoms and symptoms ﬁrst
noticed, not the symptoms ever experienced. It is possible
that some patients experienced pain at some point during
the course of the disease, but this study was not intended to
capture all symptoms ever experienced.
Regardless of the fact that patients reported a wide
array of penile symptoms, fewer than half of PD patients
reported seeking treatment. Many patients may be reluctant
to come to their physician for treatment and diagnosis of
this embarrassing condition [25]. Several factors have been
identiﬁed that predict which patients are more inclined to
delay treatment, including older age, being in a long-termAdvances in Urology 7
relationship, having a partner, being heterosexual, and the
presence of simple penile deformity [35]. Of those seeking
medical treatment for penile symptoms, most initially saw
a PCP, and the average duration of time to a doctor vis-
it was within a year and a half of noticing a penile symp-
tom. Approximately one-third of PD patients did not see a
doctor until 4 years after the emergence of penile symptoms.
Consistent with the possibility of underdiagnosis and under-
treatment of PD in the US, only 8% of PD patients received
a diagnosis of PD from the ﬁrst doctor seen; the most fre-
quentdiagnosis wasED.Approximately three-quartersofthe
patientsreceivednotreatmentfromtheﬁrstdoctorseen,and
15% received treatment related to ED. These results further
indicate that PD is not well understood, and the time to
appropriate diagnosis and treatment can be long.
The observed treatment patterns for patients with PD
include surgical and nonsurgical procedures. There are cur-
rently no FDA-approved nonsurgical options. Therefore,
physicianshavetobasetreatmentrecommendationsfornon-
surgical options on limited placebo-controlled clinical trial
support [9, 36, 37]. This may lead some physicians to oﬀer
expectant management as opposed to potentially ineﬀective
nonsurgical therapies [38]. Penile operations and injection
treatments were uncommon among PD patients. Urologists
most frequently performed these procedures, followed by
PCPs and sexual medicine specialists for injection proce-
dures. The median duration of time to receive treatment
following diagnosis of PD was approximately 2 months
earlier for injection procedures compared with surgery and,
from noticing the ﬁrst symptom, was approximately 2 and a
half months earlier for injection procedures compared with
surgery. Though surgery may be eﬀective for many patients,
it may be associated with complications and the possibility
of penile shortening with some procedures [14–16]. It is
generally reserved for patients in the chronic phase of PD
with deformity and interference in sexual function, and so
eﬀective nonsurgical treatment for PD is needed [14].
A major strength of the current study is the use of
a web-based survey to recruit a large, population-based
sampleofparticipantswhowererepresentativeofthegeneral
US adult male population, which has been lacking in the
current PD epidemiological literature. The survey had a
high response rate, and the participant responses provided
the ﬁrstavailable population-based prevalenceand incidence
estimates for PD in the US. A weakness of the current study
is the small number of participant responses for some of the
measured outcomes (e.g., surgery). Oversampling of more
severe cases of PD may have occurred in the Phase 2 survey;
all survey respondents in Phase 1 who reported a diagnosis
of PD or treatment for PD were invited to participate in
Phase 2, whereas a subsample of participants reporting
only symptoms were randomly selected for participation in
Phase 2. Finally, participants self-reported their diagnoses
and symptoms of PD through a process that allowed for
respondent conﬁdentiality (respondents were able to skip
over any questions they did not feel comfortable answering
or stop the survey at any time) which may have led to
under- or overreporting on the survey. Additional problems
with patient self-reporting could include misinterpretation
ofPD-speciﬁcsymptomsorimperfectrecallwhensymptoms
occurred.
5. Conclusion
This study is the ﬁrst large-scale, web-based population sur-
v e yo fP Da m o n gar e p r e s e n t a t i v es a m p l eo fU Sa d u l tm e n .
The patient-reported prevalence of PD ranged from 0.5% to
13%, depending on how the occurrence of PD was deﬁned.
One-third of participants reporting PD also reported inter-
ference with sexual activities. More than 90% of PD patients
whosoughtmedicalcareforpenilesymptomsdidnotreceive
adiagnosisofPD,andapproximately75%didnotreceiveany
treatment from the ﬁrst doctor seen. Study ﬁndings suggest
that PD may be underdiagnosed and undertreated in the US
and point to the need for better awareness of PD and related
treatment options among health care professionals.
Appendix
A. Peyronie’s DiseaseSurvey
Formore details see Supplementary Materialavailable online
at doi:10.1155/2011/282503.
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